# A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT02835729** · PHASE1 · COMPLETED · sponsor: **NewLink Genetics Corporation** · enrollment: 54 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Indoximod Freebase
- **DRUG:** Indoximod HCL F1
- **DRUG:** Indoximod HCL F2

## Key facts

- **NCT ID:** NCT02835729
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-12-27
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02835729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02835729, "A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02835729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*